A systematic review involving data on over 45,000 patients was not associated with an increased risk of any cancer from semaglutide when compared to a placebo group (37)
Estimated treatment differences between cohorts showed the semaglutide 2.4 mg cohort had significantly greater percentage ( 15.0%) and absolute reduction in weight ( 15.7 kg), greater reduction in BMI ( 4.2 kg/m 2 ), and significantly greater improvements in cardiometabolic risk factors, including SBP ( 6.7 mmHg), DBP ( 2.7 mmHg), HbA1c ( 0.5%), HDL-C (1.2 mg/dl), LDL-C ( 10.4 mg/dl), and triglycerides ( 34.3 mg/dl) at 12 months
Rekha Kumar, endocrinologist and associate professor of clinical medicine at Weill Cornell, told NBC's Anne Thompson during an Oct
What is also interesting is that the weight loss in the diabetic trial and non-diabetic trial of orforglipron were nearly identical at the top dose